ARTICLE | Company News
Medivation, Astellas sales and marketing update
June 8, 2015 7:00 AM UTC
The German Institute for Quality and Efficiency in Health Care (IQWiG) said Xtandi enzalutamide from Astellas has “major added benefit” in metastatic prostate cancer patients ages 75 and older that a...